Listed by the USPTO as REDWOOD, CHRISTOPHER EVAN
Tech Center 1600 • Art Units: 1629
This examiner grants 0% of resolved cases
REDWOOD, CHRISTOPHER EVAN is assigned to tech center 1600 and art unit 1629. The profile contains 2 resolved cases, a 0.0% allowance rate, and a median of 1095 days to allowance. The interview lift is 0.0%, so this limited record does not show an interview-associated change in allowance outcomes.
The listed companies are INCYTE Corporation, The Brigham and Women's Hospital Inc., and B. Braun Melsungen AG. The leading firms are MCCARTER & ENGLISH, LLP BOSTON, MYERS BIGEL, P.A., and AMIN WASSERMAN GURNANI LLP. The small case base makes broad prosecution conclusions inappropriate. Practitioners should examine the individual application record closely and avoid relying on the aggregate figures as a predictive pattern. The 1095-day median remains a planning reference for matters assigned to this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17923891 | METHODS FOR INDUCING BILE ACID SULFOTRANSFERASE SULT2A FOR TREATING METABOLIC DISORDERS | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 18558899 | DEXMEDETOMIDINE-SOLUTION IN A LOW-DENSITY POLYETHYLENE CONTAINER | Final Rejection | B. Braun Melsungen AG |
| 18353770 | BIARYL ETHER UREA COMPOUNDS | Final Rejection | Jazz Pharmaceuticals Ireland Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy0.0% of resolved applications examined by Christopher Evan Redwood were allowed (2 resolved cases), compared with 42.3% across Art Unit 1629 over the last five years.
This examiner's interview lift is +0.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Christopher Evan Redwood took 1,095 days on average from filing to allowance.
Christopher Evan Redwood examines applications in Art Unit 1629 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
